Crossmark

Risk of metastatic recurrence after endoscopic resection for esophageal squamous cell carcinoma invading into the muscularis mucosa or submucosa: a multicenter retrospective study

Crossref DOI link: https://doi.org/10.1007/s00535-021-01787-y

Published Online: 2021-04-21

Published Print: 2021-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hatta, Waku https://orcid.org/0000-0001-9717-0281
Koike, Tomoyuki

Takahashi, So

Shimada, Tomohiro

Hikichi, Takuto

Toya, Yosuke

Tanaka, Ippei

Onozato, Yusuke

Hamada, Koichi

Fukushi, Daisuke

Watanabe, Ko

Kayaba, Shoichi

Ito, Hirotaka

Mikami, Tatsuya

Oikawa, Tomoyuki

Takahashi, Yasushi

Kondo, Yutaka

Yoshimura, Tetsuro

Shiroki, Takeharu

Nagino, Ko

Hanabata, Norihiro

Funakubo, Akira

Hirasawa, Dai

Ohira, Tetsuya

Nakamura, Jun

Matsumoto, Takayuki

Nakamura, Tomohiro

Nakaya, Naoki

Iijima, Katsunori

Fukuda, Shinsaku

Masamune, Atsushi

,
License Information

Text and Data Mining valid from 2021-04-21

Version of Record valid from 2021-04-21
More Information

Article History

Received: 3 February 2021

Accepted: 13 April 2021

First Online: 21 April 2021

Declarations

:

: Atsushi Masamune declared that he received lecture honoraria from EA Pharma Co.,Ltd., Takeda Pharmaceutical Co.,Ltd., Daiichi Sankyo, Inc., and Mylan.co.jp and he received commercial research funding from Otsuka Pharmaceutical Co.,Ltd., EA Pharma Co.,Ltd., Gilead Sciences, Inc., Asahi Kasei Pharma Corp., Eisai Co.,Ltd., AbbVie GK, Takeda Pharmaceutical Co.,Ltd., and Daiichi Sankyo, Inc. outside the submitted work.

Document is current

Any future updates will be listed below